Transgene

Regulatory Filings • Dec 9, 2019

Transgene Announces Investor Meetings for January 2020

Strasbourg, France, December 9, 2019, 6:00 pm CET – Transgene (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.

Transgene will meet institutional investors at the LifeSci Advisors Corporate Access Event from January 13 to 16, 2020, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.

The Company will also attend:

• Oddo Forum: January 9 & 10, 2020 Lyon, France
• Biomed Event: January 28, 2020 Paris, France

Contacts

Transgene:

Media contacts:

Lucie Larguier	Citigate Dewe Rogerson
+33 (0)3 88 27 11 21	David Dible/Sylvie Berrebi
investorrelations@transgene.fr	transgene@citigatedewerogerson.com

About Transgene

Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, TG4001, a therapeutic vaccine against HPV-positive cancers, and TG6002, an oncolytic virus for the treatment of solid tumors.

With its proprietary platform Invir.IO®, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses. myvac™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio. TG4050, the first candidate selected from the myvac™ platform, will enter the clinic for the treatment of ovarian cancer and head and neck cancer.

Additional information about Transgene is available at: www.transgene.fr. Follow us on Twitter: @TransgeneSA